🔍
This CATHIE WOOD New Favourite $1 Penny Stock Is Still Cheap 🔥 Ark Loads Up 3 Top Penny Stocks 🔥🚀 - YouTube
Channel: Corns Investing
[0]
What’s up everyone so in today’s video,
I share with you three top penny stocks, which
[6]
Cathie Wood of Ark Invest has been loading
up on.
[8]
For those who are not familiar with Cathie
Woods investing style, they fundamentally
[13]
invest in disruptive innovative stocks for
the long term and typically go for mid to
[17]
large cap stocks with higher liquidity.
[21]
So to see them loading up on these penny stocks
at this stage, it speaks of their conviction
[26]
and strong belief on what these stocks have
to offer.
[30]
So the key here is that these penny stocks
are potential long term plays and so only
[35]
get in, if you fully understand their risks,
you like their story or business model and
[40]
if the price is right for you, as this is
not financial advise...
[45]
So make sure you don’t miss out on these
big bangers by liking the video and turn on
[49]
the notification bell to get these hot penny
stocks instantly.
[54]
And also if you want two free stocks worth
over $1800 from Webull and also where you
[59]
can buy fractional shares, please hit the
link in the top comment or description below.
[63]
I would really appreciate it.
[64]
Thank you so much.
[66]
So let’s get straight into it, with our
number 3 penny stock here, which is Purple
[71]
Biotech ADR (PPBT).
[73]
It has a share price sitting at $5.59 and
market cap of $98m.
[79]
This penny stock is up 14.5% over the last
month and YTD it is up 37.6%.
[86]
And going by its recent peaks and troughs
it seems a very sensitive stock to news and
[93]
one which could provide decent swing trade
opportunities.
[97]
It actually seems to be running up right now
on the back of latest news.
[101]
So one to wait for it to cool down as we aim
buy low and sell high.
[106]
Purple Biotech is Nasdaq Listed with an average
of 259k shares traded over a 30day period
[112]
and over 17.6m shares outstanding.
[116]
So very tightly held shares.
[118]
Purple Biotech Ltd.
[119]
(NASDAQ/TASE: PPBT) is a clinical-stage company
focused on advancing first-in-class therapies
[123]
to overcome tumor immune evasion and drug
resistance to create effective, durable treatments
[131]
for cancer patients.
[133]
They have two programmes in their pipeline:
first CM24, which is a first-in-class clinical
[140]
stage drug targeting a novel immune checkpoint
inhibitor with significant potential to treat
[146]
multiple cancers.
[148]
In a Phase 1 dose-escalation study, CM24 demonstrated
a good safety profile and promising efficacy
[155]
signals.
[156]
And they are developing CM24 in collaboration
with Bristol Myers-Squibb via a Phase 1/2
[164]
trials.
[165]
Their topline data results are expected in
the second half of 2021.
[169]
Their second programme is NT219, which is
a first-in-class, novel small molecule targeting
[176]
both important oncogenic drivers and major
drug resistance pathways in many hard-to-treat
[182]
cancers.
[184]
Ark Invest is presently holding over 737k
shares worth over $4.1m in their Israel Innovation
[192]
Tech ETF.
[194]
They started loading up on the stock on the
13th of July when it was still trading at
[198]
$4.4 and have gradually built their position
in the stock to over 700k shares.
[205]
So still very early days on the stock but
exciting times ahead as more results get released
[210]
on their two programmes.
[213]
Next up to our number 2 penny stock here,
which is Entera Bio Ltd
[217]
(ENTX).
[220]
It has a share price sitting at $5 per share
and market cap of $121m.
[227]
This penny stock is down 16.3% over the last
month but year to date it is up 303% having
[234]
had some decent jumps recently and its now
cooling down and pulling back slowly but I
[240]
don’t think it has bottomed out yet, so
certainly one to watch and strike in when
[244]
the price is right for you.
[246]
Entera is Nasdaq Listed with an average of
6.4m shares traded over a 30day period and
[252]
over 23.7m shares outstanding.
[255]
Entera is a leader in the development of orally
delivered large molecule therapeutics, for
[261]
use in areas with significant unmet medical
need where adoption of injectable therapies
[267]
is limited due to cost, convenience and compliance
challenges for patients.
[273]
Entera also licenses its technology to biopharmaceutical
companies for use with their proprietary compounds
[279]
and, to date, has established a collaboration
with Amgen Inc.
[283]
Entera recently announced Excellent Topline
Phase 2 BMD Data for EB613, as the Study Met
[291]
Its Primary and Key Secondary Endpoints.
[294]
Subjects receiving the 2.5 mg dose of EB613
showed significant dose-related increases
[301]
in bone mineral density BMD at the lumbar
spine, total hip, and femoral neck at 6 months.
[308]
EB613 is an oral formulation positioned to
be the first oral bone building (anabolic)
[314]
product to treat osteoporosis patients..
[318]
An End of Phase 2 meeting with the FDA to
review the EB613 development program is anticipated
[324]
in the coming months.
[326]
Ark Invest is presently holding over 531k
shares worth over $2.7m in their Israel Innovation
[334]
Tech ETF.
[336]
The started loading up on the stock on the
15th of July when it was still trading at
[340]
$5.2 and have gradually built their position
in the stock to over 500k.
[347]
Entera has 3 analysts covering the stock with
a strong buy rating.
[350]
The analysts mid price target of $12 per share
gives it an upside opportunity of over 140%
[357]
over the next 12 months.
[359]
So really exciting times ahead.
[362]
Next to our number 1 penny stock here, which
is Conformis Inc (CFMS).
[367]
It has a share price sitting at $1.46 and
market cap of $267.3m.
[376]
This penny stock is up 26.9% on the month
and up 121% YTD.
[382]
It has been showing strong momentum over the
last few trading days on the back of recent
[386]
news that could see it take continue to fly.
[390]
Conformis is Nasdaq Listed with an average
of 3.6m shares traded over a 30day period
[396]
and over 182.4m shares outstanding.
[400]
Conformis is a medical technology company
that uses its proprietary iFit® Image-to-Implant®
[406]
technology platform to develop, manufacture
and sell joint replacement implants that are
[413]
individually sized and shaped, or customized,
to fit each patient's unique anatomy.
[418]
Conformis offers a broad line of customized
knee and hip implants and customized pre-sterilized,
[423]
single-use instruments delivered in a single
package to the hospital.
[429]
Conformis Reported First Quarter 2021 Financial
Results, which saw Total revenue of $13.8
[436]
million, decrease of 16% year-on-year.
[440]
The decrease in revenue was driven primarily
by lower volume due to the impact of the COVID-19
[445]
pandemic on elective procedures.
[448]
Their Gross margin of 45%, was an increase
of 80 basis points year-on-year.
[454]
They announced the execution of an agreement
to enter the Asia-Pacific market through an
[459]
exclusive distribution relationship with XR
Medical Group (Hong Kong) Limited . And Under
[464]
the distribution agreement, XR Medical will
have exclusive rights for the sale, marketing,
[470]
and distribution of Conformis’ patient-specific
iTotal® total knee replacement systems.
[477]
The global market for knee joint reconstruction
is projected at more than $9 billion.
[483]
Of this total, the knee joint reconstruction
market in the Asia-Pacific region is currently
[487]
estimated to exceed $1.7 billion.
[491]
Fortune Business Insights predicts a high
growth rate for knee replacements in the region
[497]
due to the combination of the increased prevalence
of knee disorders, booming medical tourism,
[503]
increased disposable incomes, and improved
healthcare infrastructure, which is all really
[506]
exciting prospects for the outlook of this
stock.
[507]
So here’s the penny stock Ark Invest has
been loading up on the most.
[511]
They are presently holding over 12.8m shares
worth over $18.6m in their 3D Printing ETF.
[520]
Ark Invest started loading up on the penny
stock on the 14th of July when it was still
[524]
trading at $1.10 and have gradually cost averaged
in building their position in the stock to
[530]
over 12.8m shares.
[533]
Entera has 2 analysts covering the stock with
a buy rating.
[537]
And The analysts mid price target of $2.5
per share gives it an upside of over 66%;
[542]
and the upper price target of $3 gives an
upside of 100% over the next 12 months.
[549]
So reallu exciting times ahead.
[551]
So a very interesting and mindblowing prospects
ahead for these penny stocks but only consider
[557]
getting in if the price is right for you and
if you fully understand the risks.
[561]
This video is not financial advice, a buy
or a sell recommendation, but is meant to
[566]
bring some new and exciting penny stocks to
your attention for you to do your own research..
[571]
As always I would love to hear from you, so
please let me know your thoughts on these
[574]
top penny stocks in the comments section below
and what other penny stocks are catching your
[578]
eyes lately.
[579]
And If you are new to my channel please ensure
to subscribe and hit the bell so you are notified
[584]
when I upload new videos.
[586]
If you would like to see more videos like
this, please check out this video right here
[589]
or this playlist right here to watch equally
insightful content from the channel.
[593]
Thank you so much for being here and I look
forward to have you in my next video.
[597]
Thank you
Most Recent Videos:
You can go back to the homepage right here: Homepage